Indeed, CerK inhibition promoted a striking decrease in Luminal specific BT-474 cell proliferation and a significant tumor regression in the corresponding xenograft model, sustaining the idea that CerK can potentially be a good therapeutic target for primary tumors of Luminal subtype. This evidence concerns the gene CERK and neoplasm.